We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Action Plan to Enhance Self-management and Early Detection of Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients (ACZiE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00879281
Recruitment Status : Completed
First Posted : April 9, 2009
Last Update Posted : February 24, 2011
Sponsor:
Information provided by:
UMC Utrecht

Brief Summary:
The purpose of this randomized controlled trial is to evaluate the hypothesis that the 'written' action plan, a self-management tool developed by the project group, enhances early detection and prompt action measures and consequently isbeneficial in exacerbation outcome (i.e., health status recovery time).

Condition or disease Intervention/treatment
Chronic Obstructive Pulmonary Disease Behavioral: Action plan

Detailed Description:
Early detection of exacerbations by COPD patients initiating prompt interventions has shown to be clinically relevant. Until now, research failed to identify the effectiveness of a written individualized Action Plan (AP) to achieve this. The current multicenter, single-blind RCT with a follow-up period of 6 months, evaluates the hypothesis that individualized AP's reduce exacerbation recovery time. Patients are included from regular respiratory nurse visits and allocated to either usual care or an additional AP providing individualized treatment prescriptions (pharmaceutical and non-pharmaceutical) related to a colour coded symptom status (reinforcement at 1 and 4 months). Although usually not possible in self-management trials, we ensured blinding of patients, using a modified informed consent procedure in which patients give consent to postponed information. Exacerbations in both study arms are defined using the Anthonisen symptom diary-card algorithm. The Clinical COPD Questionnaire (CCQ) is assessed every 3-days. CCQ-recovery time of an exacerbation is our primary outcome. Additionally, healthcare utilisation, anxiety, depression, treatment delay, and self-efficacy are assessed at baseline, 6 and 12 months.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 233 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Action Plan to Enhance Self-management and Early Detection of Exacerbations in COPD Patients; A Multicenter RCT (ACZiE)
Study Start Date : December 2008
Primary Completion Date : September 2010
Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD
U.S. FDA Resources

Arm Intervention/treatment
No Intervention: 1 Care as usual
Regular care
Experimental: 2 Intervention
Regular Care + individualized "written" action plan to enhance self-mananagement and early detection/treatment of an exacerbation.
Behavioral: Action plan
Individualized "written" Action Plan to enhance self-management and early detection of an exacerbation.



Primary Outcome Measures :
  1. CCQ-recovery time in the event of an exacerbation(Health status recovery time) [ Time Frame: 6-months ]

Secondary Outcome Measures :
  1. Symptom recovery time in the event of an exacerbation [ Time Frame: 6 months ]
  2. Health Related Quality of Life - St George Respiratory Questionnaire [ Time Frame: baseline and 6 months follow-up ]
  3. The Hospital Anxiety and Depression Scale (HADS) [ Time Frame: baseline and 6 months follow-up ]
  4. Medical Research Council (MRC) Dyspnoea Scale [ Time Frame: baseline and 6 months follow-up ]
  5. Julius Self-Efficacy Scale [ Time Frame: baseline and 6 months follow-up ]
  6. Contact delay & treatment delay in the event of an exacerbation [ Time Frame: 6 months ]
  7. Exacerbation rates (Number of symptom-based / event-based exacerbations per patient year) [ Time Frame: 6 months ]
  8. Healthcare Utilization (The number of respiratory-related hospital admissions, hospital days, emergency room visits and scheduled and unscheduled visits or telephone calls to a RP and GP) [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio < 70%
  • age > 40 years
  • complaints of chronic cough
  • smoking history of more than 20 years or 15 pack-years
  • diagnosis of COPD as major functionally limiting disease and
  • current use of bronchodilator therapy.

Exclusion Criteria:

  • primary diagnosis of asthma
  • primary diagnosis of cardiac disease
  • presence of disease that could either effect mortality or participation in the study (e.g. confusional states).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00879281


Locations
Netherlands
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht
Utrecht, Netherlands, 3584 CX
Sponsors and Collaborators
UMC Utrecht
Investigators
Principal Investigator: Jaap C.A. Trappenburg, MSc University Medical Center Utrecht, The Netherlands
Study Chair: Gerdien D. de Weert - van Oene, PhD University Medical Center Utrecht, The Netherlands
Study Chair: Evelyn M. Monninkhof, PhD University Medical Center Utrecht, The Netherlands
Study Chair: Thierry Troosters, PhD Katholieke Universiteit Leuven
Study Chair: Jean Bourbeau, PhD McGill University, Montreal Chest Institute, Canada
Study Director: Theo J.M. Verheij, PhD University Medical Center Utrecht, The Netherlands
Study Director: Jan-Willem J. Lammers, PhD University Medical Center Utrecht, The Netherlands
Study Director: Guus J.P. Schrijvers, PhD University Medical Center Utrecht, The Netherlands